FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 328 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT... February 26, 2026 Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... January 13, 2025 Pioneer in Autism Diagnosis And Treatment Dies At 97 September 21, 2021 EMA Recommends Extension of Indications for Lorlatinib December 20, 2021 Load more HOT NEWS ¿Qué deben saber las personas con cáncer sobre el consumo de... First immunotherapy approved for cervical cancer in England and Scotland Immunotherapy, Liquid Biopsy, and Treatment Combinations: Research from the 2024 ASCO... Some Brain Cells May Help to Fuel Cancer Metastasis
